Cargando…
Clozapine-Induced Myocarditis: Is Mandatory Monitoring Warranted for Its Early Recognition?
Clozapine is an atypical antipsychotic used for treatment resistant schizophrenia. Its potential to induce agranulocytosis is well known but it can also cause myocarditis. Clozapine is the only antipsychotic known to induce this side effect, typically early in the treatment, and literature is scarce...
Autores principales: | Munshi, T. A., Volochniouk, D., Hassan, T., Mazhar, N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920926/ https://www.ncbi.nlm.nih.gov/pubmed/24587933 http://dx.doi.org/10.1155/2014/513108 |
Ejemplares similares
-
Clozapine-induced myocarditis
por: Datta, Tanuka, et al.
Publicado: (2018) -
Clozapine-induced myocarditis: Two case reports and review of clinical presentation and recognition
por: Sackey, Bryan K., et al.
Publicado: (2018) -
Clozapine Monitoring in Clinical Practice: Beyond the Mandatory Requirement
por: Kar, Nilamadhab, et al.
Publicado: (2016) -
Clozapine reinitiation following a “red result” secondary to chemotherapy
por: Munshi, Tariq, et al.
Publicado: (2013) -
Mandatory certification for clozapine prescribing
por: Cohen, Dan, et al.
Publicado: (2020)